Crucell, DSM Expand Development Pact

DSM Biologics and Crucell have entered an agreement to expand the existing commercial relationship for their PER.C6 collaboration to include new classes of proteins, including biosimilar protein products. As part of the agreement, Crucell received an undisclosed amount in exchange for additional license rights and a higher share of future licensing income.

Since December 2002, the two companies jointly outlicense PER.C6 human cell line to third parties as a production platform for monoclonal antibodies and recombinant proteins. They recently established the PERCIVIA PER.C6 Development Center in Cambridge, MA as a joint venture to further develop the PER.C6 cell line and to provide production solutions for pharmaceutical proteins to licensees using the PER.C6 human cell line in the biotech industry.